Results 1 to 10 of about 18,181 (226)

Biosimilar uptake policies in Europe: a cross-country mixed-methods policy analysis [PDF]

open access: yesThe Lancet Regional Health. Europe
Summary: Background: European countries implemented a range of policies to enhance uptake of biosimilar medicines, which are interchangeable with the originator but usually offer biological therapies at lower cost.
Sabine Vogler   +16 more
doaj   +2 more sources

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

open access: yesBiomedicines, 2022
This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness.
Luca Carmisciano   +2 more
exaly   +3 more sources

Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy

open access: yesmAbs, 2022
The α-Gal epitope consisting of the terminal trisaccharide Galα1,3Galβ1,4GlcNAc exposed on cell or protein surfaces can cause severe immune reactions, such as hypersensitivity reactions, in humans.
Arthur Hinterholzer   +6 more
doaj   +1 more source

Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain

open access: yesPharmaceuticals, 2021
Incentives contribute to the proper functioning of the broader contracts that regulate the relationships between health systems and professionals.
Félix Lobo, Isabel Río-Álvarez
doaj   +1 more source

An international comparative analysis and roadmap to sustainable biosimilar markets

open access: yesFrontiers in Pharmacology, 2023
Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability of biosimilar markets.
Khalid A. Alnaqbi   +22 more
doaj   +1 more source

Knowledge and Perception of Iraqi Pharmacists Towards Biosimilar Medicines

open access: yesIraqi Journal of Pharmaceutical Sciences, 2021
Biosimilars are non-innovative copy versions of biologic medicines which are proven to be clinically equivalent to, as effective and as safe as their reference biologics.
Ashwaq J. Mohammed, Dheyaa J. Kadhim
doaj   +1 more source

TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System

open access: yesScientific Reports, 2022
TNF-alpha inhibitors have revolutionized the therapeutic care in chronic inflammatory diseases. Several biosimilar products were commercialized at their patent expiry, substantially decreasing the cost of treatment.
Hugo Jourdain   +3 more
doaj   +1 more source

Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution

open access: yesPLoS ONE, 2022
Healthcare systems have reached a critical point regarding the question of whether biosimilar substitution should become common practice. To move the discussion forward, the study objective was to investigate the views of experts from medicines agencies ...
Louise C. Druedahl   +6 more
doaj   +2 more sources

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar

open access: yesTherapeutic Advances in Gastroenterology, 2023
Background: Many patients with inflammatory bowel disease (IBD) have transitioned from an infliximab originator to a biosimilar. However, some patients retransition to the originator (i.e. stop biosimilar and reinitiate the originator). Whether this sign
Rosanne W. Meijboom   +6 more
doaj   +1 more source

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

open access: yesPharmaceutics, 2020
Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation undergone prior
Ioana Gherghescu   +1 more
doaj   +1 more source

Home - About - Disclaimer - Privacy